JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from immature lymphocytes that show uncontrolled proliferation and arrested differentiation. Genomic alterations affecting Janus kinase 2 (JAK2) correlate with some of the poorest outcomes within the Philadelphia-like su...

Full description

Bibliographic Details
Main Authors:	Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung, Deborah L. White
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	leukemia Janus kinases kinase inhibitor JAK2 targeted therapy acute lymphoblastic leukemia
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2022.942053/full

Similar Items

Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis
by: Susan L. Heatley, et al.
Published: (2022-04-01)

A Novel Homozygous Nucleotide Deletion in the JAK2 Gene in a Pediatric Patient with B-cell Precursor Acute Lymphoblastic Leukemia
by: Dilara Fatma Akın, et al.
Published: (2012-05-01)

Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression
by: Elyse C. Page, et al.
Published: (2023-07-01)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
by: Srdan Verstovsek, et al.
Published: (2017-02-01)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
by: Charlotte E. J. Downes, et al.
Published: (2021-08-01)

Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
by: James L. Januzzi, et al.
Published: (2022-01-01)

High Expression of PKM2 Was Associated with the Poor Prognosis of Acute Leukemia
by: Huang Y, et al.
Published: (2021-10-01)

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
by: David E. Spaner, et al.
Published: (2019-04-01)

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
by: Nem Kumar Jain, et al.
Published: (2023-03-01)

RETRACTED: The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics
by: Elham Zeinalzadeh, et al.
Published: (2021-12-01)

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies
by: Eric L. Simpson, et al.
Published: (2024-07-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).
by: Jacqueline Rehn, et al.
Published: (2022-10-01)

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
by: Michelle Le, et al.
Published: (2021-09-01)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
by: Ronan Talty, BS, et al.
Published: (2021-10-01)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
by: Eric Toussirot
Published: (2022-02-01)

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies
by: Toshiaki Kogame, et al.
Published: (2023-07-01)

Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis
by: Yu. S. Kovaleva, et al.
Published: (2022-03-01)

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
by: Juuli Raivola, et al.
Published: (2018-12-01)

Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy
by: Katelyn Singh, BS, et al.
Published: (2021-01-01)

Sisaipho alopecia areata treated with tofacitinib and oral minoxidil
by: Ronan Talty, BS, et al.
Published: (2022-11-01)

Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
by: C. Garcia-Melendo, et al.
Published: (2021-06-01)

Refractory pityriasis rubra pilaris treated with abrocitinib
by: Filip Rob
Published: (2025-01-01)

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening
by: Angelika Pölläniemi, et al.
Published: (2023-06-01)

Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid
by: William Damsky, MD, PhD, et al.
Published: (2020-02-01)

Adherence to Oral Chemotherapy in Acute Lymphoblastic Leukemia during Maintenance Therapy in Children, Adolescents, and Young Adults: A Systematic Review
by: Xiaopei L. Zeng, et al.
Published: (2023-01-01)

Upadacitinib as Novel Treatment for Rheumatoid Arthritis with T-Cell Granular Lymphocytic Leukemia: A Case Report and Narrative Review
by: Young Min Cho, et al.
Published: (2022-07-01)

Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia
by: Lu Wang, et al.
Published: (2017-01-01)

Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family
by: Amir Taldaev, et al.
Published: (2021-12-01)

Immunolocalization and Expression of JAK1 and JAK3 in the Skin of Dust Mite-Sensitive Beagle Dogs before and after Allergen Exposure
by: Roberta Sartori, et al.
Published: (2023-08-01)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
by: Huo R, et al.
Published: (2023-04-01)

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo
by: David E. Spaner, et al.
Published: (2023-04-01)

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
by: I-Hsin Huang, et al.
Published: (2022-12-01)

Biologic and Small Molecule Therapy in Atopic Dermatitis
by: Mahek Shergill, et al.
Published: (2024-08-01)

Ruxolitinib cream for the treatment of granuloma annulare
by: Austin J. Piontkowski, BS, et al.
Published: (2024-08-01)

Truncal acne following JAK inhibitor use in vitiligo with rare opportunistic fungal infections: Two case reports
by: Jee Yun Doh, MD, et al.
Published: (2023-07-01)

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
by: Vijairam Selvaraj, et al.
Published: (2022-07-01)

Ruxolitinib found to cause eyelash growth: a case report
by: Julia Song, et al.
Published: (2017-07-01)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
by: Novella Pugliese, et al.
Published: (2019-06-01)

Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib
by: Sa Rang Kim, MD, et al.
Published: (2021-10-01)